ORTX Orchard Therapeutics plc

11.97
+0.49  (+4%)
Previous Close 11.48
Open 11.63
Price To Book 3.4
Market Cap 1,155,314,882
Shares 96,517,534
Volume 481,587
Short Ratio
Av. Daily Volume 211,695
Stock charts supplied by TradingView

NewsSee all news

  1. Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy

    BOSTON and LONDON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  2. European Medicines Agency Grants Orchard Therapeutics Accelerated Assessment of OTL-200 for Patients with Metachromatic Leukodystrophy

    BOSTON and LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  3. Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises

    ASH Abstracts Published Today Confirm Achievement of All Key Endpoints in Wiskott-Aldrich Syndrome Registrational Trial and Demonstrate Consistency of Data Between the Fresh and Cryopreserved Formulations of

  4. Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting

    Registrational Trial for Wiskott-Aldrich Syndrome Met Key Primary and Secondary Endpoints at Three Years; Data from Integrated Analysis Reinforce Treatment Benefits of Gene Therapy and Durability of Effect in Additional

  5. Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results

    BOSTON and LONDON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data to be presented February 24, 2019.
OTL-102
X-linked chronic granulomatous disease (X-CGD)
Phase 1/2 engraftment data due 2019.
OTL-101
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Phase 1/2 data presented April 29, 2019.
OTL-300
Transfusion-dependent beta-thalassemia (TDBT)
Phase 2 data presented at ESGCT October 2019.
OTL-200
Metachromatic leukodystrophy (MLD)
Phase 1/2 presentation at ASH December 8, 6pm ET.
OTL-103
Wiskott-Aldrich Syndrome (WAS)
Phase 1 data to be presented at ASH December 9, 2019 7am ET.
OTL-203
MPS I

Latest News

  1. Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy

    BOSTON and LONDON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  2. European Medicines Agency Grants Orchard Therapeutics Accelerated Assessment of OTL-200 for Patients with Metachromatic Leukodystrophy

    BOSTON and LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  3. Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises

    ASH Abstracts Published Today Confirm Achievement of All Key Endpoints in Wiskott-Aldrich Syndrome Registrational Trial and Demonstrate Consistency of Data Between the Fresh and Cryopreserved Formulations of

  4. Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting

    Registrational Trial for Wiskott-Aldrich Syndrome Met Key Primary and Secondary Endpoints at Three Years; Data from Integrated Analysis Reinforce Treatment Benefits of Gene Therapy and Durability of Effect in Additional

  5. Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results

    BOSTON and LONDON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  6. Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation

    Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations Regulatory Submission in Europe

  7. Orchard Therapeutics Announces Appointment of CEO Mark Rothera to The Alliance for Regenerative Medicine's 2020 Board of Directors

    BOSTON and LONDON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  8. Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress

    BOSTON and LONDON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  9. Orchard Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and

  10. Orchard Therapeutics Announces Departure of Chief Commercial Officer

    BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and